Abstract
Background: Various malignancies can be efficiently combated by focusing on glutathione. It is unclear how glutathione-related genes link to diffuse large B-cell lymphoma (DLBCL). Methods: Clinical information was gathered from DLBCL patients, and differences in glutathione-related differentially expressed genes (DEGs) between DLBCL and healthy groups were found. Enrichment analysis was run on the DEGs associated with glutathione. We discovered hub genes in glutathione, confirmed hub genes’ capacity for diagnosis and function prediction, and estimated drug sensitivity. Immune microenvironmental variations between healthy and DLBCL people were assessed, and hub genes for transcription factor (TF) targeting and miRNAs were found. Results: The glutathione-related DEGs were linked to biological processes such as response to oxidative stress and response to xenobiotic stimulus, according to enrichment analysis. Out of DEGs associated with glutathione, six hub genes were chosen. In the DLBCL population, there was a notable upregulation of the six hub genes. All the genes’ AUC values in the diagnostic ability category were more than 0.7, showing strong hub gene diagnostic capacity. The DLBCL population had a high level of T-cell infiltration, according to immune infiltration analysis techniques. Similar activities, such as the cell cycle G2/M phase transition and the negative control of organelle formation, are demonstrated by gene function prediction for hub. According to drug sensitivity prediction, there was a favorable link between KPNA2 with pracinostat, BRCA1 with B-7100, and LEE-011. The gene KPNA2 was shown to be concurrently targeted by many miRNAs and TFs, according to the miRNA-gene-TF interaction network. Conclusion: The relationship between DLBCL and glutathione-related genes was uncovered by our research, and six glutathione genes were linked to DLBCL. These genes might be used as diagnostic biomarkers or targets for treatment for DLBCL patients.
Journal Section:
Original Article
References
1.
Frontzek
F
, Staiger
AM
, Wullenkord
R
, Grau
M
, Zapukhlyak
M
, Kurz
KS
, et al. Molecular profiling of EBV associated diffuse large B-cell lymphoma
. Leukemia
. 2023
;37
(3
):670
–9
. 2.
Ye
X
, Wang
L
, Nie
M
, Wang
Y
, Dong
S
, Ren
W
, et al. A single-cell atlas of diffuse large B cell lymphoma
. Cell Rep
. 2022
;39
(3
):110713
. 3.
Ernst
M
, Oeser
A
, Besiroglu
B
, Caro-Valenzuela
J
, Abd El Aziz
M
, Monsef
I
, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
. Cochrane Database Syst Rev
. 2021
;9
(9
):Cd013365
. 4.
Miyawaki
K
, Kato
K
, Sugio
T
, Sasaki
K
, Miyoshi
H
, Semba
Y
, et al. A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
. Blood Adv
. 2022
;6
(7
):2388
–402
. 5.
Wright
GW
, Huang
DW
, Phelan
JD
, Coulibaly
ZA
, Roulland
S
, Young
RM
, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
. Cancer Cell
. 2020
;37
(4
):551
–68.e14
. 6.
Chapuy
B
, Stewart
C
, Dunford
AJ
, Kim
J
, Kamburov
A
, Redd
RA
, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
. Nat Med
. 2018
;24
(5
):679
–90
. 7.
Pacis
S
, Bolzani
A
, Heuck
A
, Gossens
K
, Kruse
M
, Fritz
B
, et al. Epidemiology and real-world treatment of incident diffuse large B-cell lymphoma (DLBCL): a German claims data analysis
. Oncol Ther
. 2024
;12
(2
):293
–309
. 8.
Eyre
TA
, Wilson
W
, Kirkwood
AA
, Wolf
J
, Hildyard
C
, Plaschkes
H
, et al. Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
. Blood Adv
. 2021
;5
(8
):2229
–36
. 9.
Doraiswamy
A
, Shah
MR
, Bannerji
R
. Immunotherapies old and new: hematopoietic stem cell transplant, chimeric antigen receptor T cells, and bispecific antibodies for the treatment of relapsed/refractory diffuse large B cell lymphoma
. Curr Hematol Malig Rep
. 2021
;16
(1
):72
–81
. 10.
Hutchings
M
. The evolving therapy of DLBCL: bispecific antibodies
. Hematol Oncol
. 2023
;41
(S1
):107
–11
. 11.
Morschhauser
F
, Feugier
P
, Flinn
IW
, Gasiorowski
R
, Greil
R
, Illés
Á
, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
. Blood
. 2021
;137
(5
):600
–9
. 12.
Forman
HJ
, Zhang
H
, Rinna
A
. Glutathione: overview of its protective roles, measurement, and biosynthesis
. Mol Aspects Med
. 2009
;30
(1–2
):1
–12
. 13.
Lv
H
, Zhen
C
, Liu
J
, Yang
P
, Hu
L
, Shang
P
. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy
. Oxid Med Cell Longev
. 2019
;2019
:3150145
. 14.
Kennedy
L
, Sandhu
JK
, Harper
ME
, Cuperlovic-Culf
M
. Role of glutathione in cancer: from mechanisms to therapies
. Biomolecules
. 2020
;10
(10
):1429
. 15.
Nunes
SC
, Serpa
J
. Glutathione in ovarian cancer: a double-edged sword
. Int J Mol Sci
. 2018
;19
(7
):1882
. 16.
Ogiwara
H
, Takahashi
K
, Sasaki
M
, Kuroda
T
, Yoshida
H
, Watanabe
R
, et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers
. Cancer Cell
. 2019
;35
(2
):177
–90 e8
. 17.
Wang
SF
, Chang
YL
, Fang
WL
, Li
AFY
, Chen
CF
, Yeh
TS
, et al. Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer
. Cancer Sci
. 2023
;114
(8
):3301
–17
. 18.
Atanaskovic
L
, Cikota-Aleksic
B
, Tarabar
O
, Trimcev
J
, Zivanovic-Ivic
A
, Marjanovic
S
, et al. Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma
. J BUON
. 2016
;21
(6
):1459
–65
.19.
Takahara
T
, Nakamura
S
, Tsuzuki
T
, Satou
A
. The immunology of DLBCL
. Cancers
. 2023
;15
(3
):835
. 20.
Rotaru
I
, Tănase
AD
, Nacea
JG
, Pătraşcu
Ş
, Olteanu
OA
, Pătraşcu
AM
. Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy
. Rom J Morphol Embryol
. 2019
;60
(1
):41
–8
.21.
Zhang
J
, Gu
Y
, Chen
B
. Drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory DLBCL
. Cancer Manag Res
. 2023
;15
:245
–55
. 22.
Bansal
A
, Simon
MC
. Glutathione metabolism in cancer progression and treatment resistance
. J Cell Biol
. 2018
;217
(7
):2291
–8
. 23.
Han
Y
, Wang
X
. The emerging roles of KPNA2 in cancer
. Life Sci
. 2020
;241
:117140
. 24.
Shen
X
, Shen
X
. A potential role for aspirin in the prevention and treatment of cholangiocarcinoma
. Int J Cancer
. 2021
;148
(6
):1323
–30
. 25.
Zheng
S
, Li
X
, Deng
T
, Liu
R
, Bai
J
, Zuo
T
, et al. KPNA2 promotes renal cell carcinoma proliferation and metastasis via NPM
. J Cell Mol Med
. 2021
;25
(19
):9255
–67
. 26.
Islam
S
, Paek
AL
, Hammer
M
, Rangarajan
S
, Ruijtenbeek
R
, Cooke
L
, et al. Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
. Oncotarget
. 2018
;9
(89
):35875
–90
. 27.
Jian
W
, Deng
XC
, Munankarmy
A
, Borkhuu
O
, Ji
CL
, Wang
XH
, et al. KIF23 promotes triple negative breast cancer through activating epithelial-mesenchymal transition
. Gland Surg
. 2021
;10
(6
):1941
–50
. 28.
Gong
Y
, Zhou
L
, Ding
L
, Zhao
J
, Wang
Z
, Ren
G
, et al. KIF23 is a potential biomarker of diffuse large B cell lymphoma: analysis based on bioinformatics and immunohistochemistry
. Medicine
. 2022
;101
(24
):e29312
. 29.
Yoshida
K
, Miki
Y
. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage
. Cancer Sci
. 2004
;95
(11
):866
–71
. 30.
Kanakkanthara
A
, Kurmi
K
, Ekstrom
TL
, Hou
X
, Purfeerst
ER
, Heinzen
EP
, et al. BRCA1 deficiency upregulates NNMT, which reprograms metabolism and sensitizes ovarian cancer cells to mitochondrial metabolic targeting agents
. Cancer Res
. 2019
;79
(23
):5920
–9
. 31.
Shen
M
, Zheng
T
, Lan
Q
, Zhang
Y
, Zahm
SH
, Wang
SS
, et al. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut
. Hum Genet
. 2006
;119
(6
):659
–68
. 32.
Ozcalimli
A
, Erdoğdu
İH
, Turgutkaya
A
, Yavaşoğlu
İ
, Döger
FK
, Bolaman
AZ
. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma
. Int J Lab Hematol
. 2023
;45
(3
):310
–6
. 33.
Duan
Y
, Fu
H
, Huang
J
, Yin
N
, Liu
L
, Liu
X
. TOP2A deficiency leads to human recurrent spontaneous abortion and growth retardation of mouse pre-implantation embryos
. Mol Med
. 2022
;28
(1
):165
. 34.
Zhang
Y
, Yang
H
, Wang
L
, Zhou
H
, Zhang
G
, Xiao
Z
, et al. TOP2A correlates with poor prognosis and affects radioresistance of medulloblastoma
. Front Oncol
. 2022
;12
:918959
. 35.
Pedersen
MO
, Poulsen
TS
, Gang
AO
, Knudsen
H
, Lauritzen
AF
, Pedersen
M
, et al. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma
. Exp Hematol
. 2015
;43
(7
):534
–6
. 36.
Chen
B
, Mao
T
, Qin
X
, Zhang
W
, Watanabe
N
, Li
J
. Role of estrogen receptor signaling pathway-related genes in diffuse large B-cell lymphoma and identification of key targets via integrated bioinformatics analysis and experimental validation
. Front Oncol
. 2022
;12
:1029998
. 37.
Li
AH
, Chen
YQ
, Chen
YQ
, Song
Y
, Li
D
. CCNB1 and CCNB2 involvement in the pathogenesis of psoriasis: a bioinformatics study
. J Int Med Res
. 2022
;50
(8
):3000605221117138
. 38.
Obermann
EC
, Went
P
, Pehrs
AC
, Tzankov
A
, Wild
PJ
, Pileri
S
, et al. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma
. Oncol Rep
. 2005
;14
(6
):1461
–7
.39.
Xiang
B
, Chen
ML
, Gao
ZQ
, Mi
T
, Shi
QL
, Dong
JJ
, et al. CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor
. BMC Med Genomics
. 2023
;16
(1
):189
. 40.
Fang
L
, Liu
Q
, Cui
H
, Zheng
Y
, Wu
C
. Bioinformatics analysis highlight differentially expressed CCNB1 and PLK1 genes as potential anti-breast cancer drug targets and prognostic markers
. Genes
. 2022
;13
(4
):654
. 41.
Rong
MH
, Li
JD
, Zhong
LY
, Huang
YZ
, Chen
J
, Xie
LY
, et al. CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle
. Exp Biol Med
. 2022
;247
(5
):395
–408
. 42.
Xi
Q
, Huang
M
, Wang
Y
, Zhong
J
, Liu
R
, Xu
G
, et al. The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer
. Tumour Biol
. 2015
;36
(7
):4939
–48
. 43.
Zhu
QY
. Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma
. Sci Rep
. 2023
;13
(1
):6310
. 44.
Dai
L
, Fan
G
, Xie
T
, Li
L
, Tang
L
, Chen
H
, et al. Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma
. Biomark Res
. 2024
;12
(1
):58
. 45.
Sidwell
RW
, Huffman
JH
, Khare
GP
, Allen
LB
, Witkowski
JT
, Robins
RK
. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
. Science
. 1972
;177
(4050
):705
–6
. 46.
Borden
KL
, Culjkovic-Kraljacic
B
. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond
. Leuk Lymphoma
. 2010
;51
(10
):1805
–15
. 47.
Zhang
Q
, Yang
R
, Tian
Y
, Ge
S
, Nan
X
, Zhu
S
, et al. Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5
. Basic Clin Pharmacol Toxicol
. 2022
;131
(1
):18
–33
. 48.
Coffman
LG
, Orellana
TJ
, Liu
T
, Frisbie
LG
, Normolle
D
, Griffith
K
, et al. Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
. JCI Insight
. 2022
;7
(18
):e160573
. 49.
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
.N Engl J Med
, 2018
. 379
(26
):2582
. 50.
Lu
YS
, Im
SA
, Colleoni
M
, Franke
F
, Bardia
A
, Cardoso
F
, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial
. Clin Cancer Res
. 2022
;28
(5
):851
–9
. 51.
Hortobagyi
GN
, Stemmer
SM
, Burris
HA
, Yap
YS
, Sonke
GS
, Hart
L
, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer
. N Engl J Med
. 2022
;386
(10
):942
–50
. 52.
Herrera-Martinez
M
, Orozco-Samperio
E
, Montaño
S
, Ariza-Ortega
JA
, Flores-García
Y
, López-Contreras
L
. Vorinostat as potential antiparasitic drug
. Eur Rev Med Pharmacol Sci
. 2020
;24
(13
):7412
–9
. 53.
Patra
S
, Praharaj
PP
, Klionsky
DJ
, Bhutia
SK
. Vorinostat in autophagic cell death: a critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention
. Drug Discov Today
. 2022
;27
(1
):269
–79
. 54.
Hsieh
TH
, Hsu
CY
, Wu
CW
, Wang
SH
, Yeh
CH
, Cheng
KH
, et al. Vorinostat decrease M2 macrophage polarization through ARID1A(6488delG)/HDAC6/IL-10 signaling pathway in endometriosis-associated ovarian carcinoma
. Biomed Pharmacother
. 2023
;161
:114500
. 55.
Works
MG
, Yin
F
, Yin
CC
, Yiu
Y
, Shew
K
, Tran
TT
, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis
. J Immunol
. 2014
;193
(7
):3278
–87
. 56.
McGonigle
S
, Chen
Z
, Wu
J
, Chang
P
, Kolber-Simonds
D
, Ackermann
K
, et al. E7449: a dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
. Oncotarget
. 2015
;6
(38
):41307
–23
. 57.
Chalmers
AJ
. The potential role and application of PARP inhibitors in cancer treatment
. Br Med Bull
. 2009
;89
:23
–40
. 58.
Ganai
SA
. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance
. Pharm Biol
. 2016
;54
(9
):1926
–35
. 59.
Liang
XL
, Ouyang
L
, Yu
NN
, Sun
ZH
, Gui
ZK
, Niu
YL
, et al. Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofission
. J Pharm Anal
. 2023
;13
(10
):1168
–82
. 60.
Lei
X
, Khatri
I
, de Wit
T
, de Rink
I
, Nieuwland
M
, Kerkhoven
R
, et al. CD4(+) helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
. Nat Commun
. 2023
;14
(1
):217
. 61.
Mami-Chouaib
F
, Blanc
C
, Corgnac
S
, Hans
S
, Malenica
I
, Granier
C
, et al. Resident memory T cells, critical components in tumor immunology
. J Immunother Cancer
. 2018
;6
(1
):87
. 62.
Buck
MD
, Sowell
RT
, Kaech
SM
, Pearce
EL
. Metabolic instruction of immunity
. Cell
. 2017
;169
(4
):570
–86
. 63.
Hedrick
CC
, Malanchi
I
. Neutrophils in cancer: heterogeneous and multifaceted
. Nat Rev Immunol
. 2022
;22
(3
):173
–87
. 64.
Lu
TX
, Rothenberg
ME
. MicroRNA
. J Allergy Clin Immunol
. 2018
;141
(4
):1202
–7
. 65.
Papavassiliou
KA
, Papavassiliou
AG
. Transcription factor drug targets
. J Cell Biochem
. 2016
;117
(12
):2693
–6
. 66.
Li
L
, Wei
D
, Zhang
J
, Deng
R
, Tang
J
, Su
D
. miR-641 inhibited cell proliferation and induced apoptosis by targeting NUCKS1/PI3K/AKT signaling pathway in breast cancer
. Comput Math Methods Med
. 2022
;2022
:5203839
. 67.
Li
C
, Zhu
Z
, Hou
Q
, Wang
B
, Zou
L
, Liu
L
, et al. Revealing potential immunotherapy targets through analysis of a ceRNA network in human colon adenocarcinoma
. Transl Cancer Res
. 2021
;10
(12
):5319
–36
. 68.
Yang
C
, Deng
SP
. [Mechanism of hsa-miR-302a-3p-targeted VEGFA in the inhibition of proliferation of gastric cancer cell]
. Sichuan Da Xue Xue Bao Yi Xue Ban
. 2019
;50
(1
):13
–9
.69.
Shen
P
, Cao
X
, Sun
L
, Qian
Y
, Wu
B
, Wang
X
, et al. KLF9 suppresses cell growth and induces apoptosis via the AR pathway in androgen-dependent prostate cancer cells
. Biochem Biophys Rep
. 2021
;28
:101151
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
